Press release
Chronic Refractory Cough Pipeline 2024 | GSK, Trevi Therapeutics
Discover the latest drugs and treatment options in the Chronic Refractory Cough Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Refractory Cough Pipeline Outlook [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Chronic Refractory Cough Pipeline Report
* July 2024:- Trevi Therapeutics - A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough. A 2-period crossover study for the treatment of cough in patients with Refractory Chronic Cough via Nalbuphine ER (NAL ER).
* July 2024:- Nocion Therapeutics- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults With Refractory or Unexplained Chronic Cough. This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
* July 2024:- Genentech Inc.:- A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough. This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.
* DelveInsight's Chronic Refractory Cough pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Chronic Refractory Cough treatment.
* The leading Chronic Refractory Cough Companies such as GSK, Trevi Therapeutics , and others.
* Promising Chronic Refractory Cough Therapies such as GDC-6599, ME-015 (Suplatast Tosilate), HS-10383, NOC-110, BLU-5937, Nalbuphine ER, and others.
Stay ahead with the most recent pipeline outlook for Chronic Refractory Cough. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chronic Refractory Cough Treatment Drugs [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Refractory Cough Emerging Drugs Profile
* GSK5464714: GSK
Camlipixant, also known as BLU-5937 or GSK-5464714, is an orally available small molecule developed by BELLUS Health, a subsidiary of GSK. It is a P2X3 receptor antagonist targeting chronic cough and other related disorders. In a phase 2b parallel group study, patients with =25 coughs per hour who received 50 mg or 200 mg of camlipixant twice daily had a 34% greater reduction in 24-hour cough frequency compared to placebo. Approximately 5% of patients on any of the three camlipixant doses experienced dysgeusia (taste disturbance), which is lower than other P2X3 antagonists. GSK recently acquired BELLUS Health, the company developing camlipixant, for $2 billion. GSK cited camlipixant's potential to be a best-in-class treatment for RCC with significant sales potential. Camlipixant is currently in Phase III stage of clinical trial evaluation for the treatment of Chronic Refractory Cough.
Explore groundbreaking therapies and clinical trials in the Chronic Refractory Cough Pipeline. Access DelveInsight's detailed report now! @ New Chronic Refractory Cough Drugs [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Refractory Cough pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Chronic Refractory Cough Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Chronic Refractory Cough Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Refractory Cough Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Chronic Refractory Cough Pipeline Report
* Coverage- Global
* Chronic Refractory Cough Companies- GSK, Trevi Therapeutics, and others.
* Chronic Refractory Cough Therapies- GDC-6599, ME-015 (Suplatast Tosilate), HS-10383, NOC-110, BLU-5937, Nalbuphine ER, and others.
* Chronic Refractory Cough Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chronic Refractory Cough Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Chronic Refractory Cough Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Refractory Cough Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Chronic Refractory Cough: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chronic Refractory Cough- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* GSK5464714: GSK
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Chronic Refractory Cough Key Companies
* Chronic Refractory Cough Key Products
* Chronic Refractory Cough- Unmet Needs
* Chronic Refractory Cough- Market Drivers and Barriers
* Chronic Refractory Cough- Future Perspectives and Conclusion
* Chronic Refractory Cough Analyst Views
* Chronic Refractory Cough Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-refractory-cough-pipeline-2024-gsk-trevi-therapeutics]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Refractory Cough Pipeline 2024 | GSK, Trevi Therapeutics here
News-ID: 3607844 • Views: …
More Releases from ABNewswire
Gold Prices Are Rising Again - Gilbert Gold Buyers Encourages Arizona Residents …
With gold prices rising, Gilbert Gold Buyers urges residents in Gilbert, Mesa, Chandler, and Tempe to sell unwanted gold and silver. The trusted Arizona gold dealer pays top dollar - no amount too small.
As gold prices surge once again, Gilbert Gold Buyers, a trusted and established gold dealer in Gilbert, Arizona, is encouraging residents throughout the East Valley to take advantage of the rising market. With values climbing and buyer…
Nouvelle Towns Launches in Oshawa, Offering Attainable Entry Into First-Time Hom …
Boutique 26-suite townhome community in Oshawa offers attainable first-time ownership and wealth-building.
Image: https://www.abnewswire.com/upload/2025/12/f1bbe2ebd72604b777c34571e5bf3779.jpg
Oshawa, Ontario - In a market where many first-time buyers feel shut out, Build Up Development Co. is redefining the entry point to homeownership with the launch of Nouvelle Towns, a 27-suite modern townhome community in North Oshawa. The project emphasizes long-term wealth-building potential through homeownership, placing first-time buyers on a path toward generational wealth.
Your first home isn't…
Ecuadorian Rainforest Joins the Organic Trade Association at Food Ingredients Eu …
The company highlights the strength of the U.S. organic sector while connecting with global buyers in Paris.
Image: https://www.abnewswire.com/upload/2025/12/c03e2070716870008c105c5ebccafded.jpg
Clifton, NJ - Ecuadorian Rainforest, LLC participated alongside the Organic Trade Association (OTA) at Food Ingredients Europe 2025 in Paris, France. The event brought together international food and nutrition professionals, offering a valuable platform for showcasing the depth and quality of U.S. organic ingredients.
The company reported a successful show, noting strong interest in…
League Sources Confirm Spurs and Bucks Engaged in Giannis Antetokounmpo Trade Di …
San Antonio, TX - In a significant development that marks the most substantive movement in years of speculation, league sources confirm that the San Antonio Spurs and Milwaukee Bucks have recently discussed a potential trade centered around two-time MVP Giannis Antetokounmpo. The conversations, described as focused and serious, represent the closest the NBA has come to a legitimate Antetokounmpo trade framework since rumors began circulating in 2020.
The news was first…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
